Core Insights - XOMA Royalty Corporation reported over $50 million in cash receipts for the full year 2025, with a 9% increase in total receipts and a significant 68% rise in royalties compared to 2024 [1][7] - The company added 22 assets to its portfolio, including five programs in advanced Phase 2 or Phase 3 development [1][3] - A stock buyback program was executed, repurchasing 648,048 shares for a total of $16 million [1][3] - XOMA completed seven acquisitions, generating $11.7 million in non-dilutive capital and gaining economic interests in potential milestone payments of up to $1.1 billion [1][6] - Key pipeline events for 2026 include anticipated Phase 2b data from volixibat and Phase 3 data from ersodetug, along with potential EMA decisions on marketing authorizations for OJEMDA™ and MIPLYFFA™ [1][4] Financial Performance - In Q4 2025, XOMA Royalty received $3.2 million from royalties and $3.3 million from milestone payments, with a total of $50.5 million in cash receipts for the full year [7][8] - The company reported income and revenues of $13.8 million for Q4 2025, up from $8.7 million in Q4 2024, and $52.1 million for the full year 2025, compared to $28.5 million in 2024 [8][14] - General and administrative expenses increased to $10.4 million in Q4 2025 from $7.0 million in Q4 2024, primarily due to higher business development costs [9][10] Business Development - XOMA amended its collaboration with Takeda, which will yield low to mid-single-digit royalties and potential milestones of up to $852.6 million across nine development-stage assets [6] - The company has been active in acquisitions, completing seven since the beginning of 2025, which has strengthened its portfolio and financial position [6][11] Cash Position - As of December 31, 2025, XOMA Royalty had cash and cash equivalents of $133.7 million, including $50.8 million in restricted cash [15][29] - The company experienced a net increase in cash of $27.3 million during the year, compared to a decrease of $53.1 million in 2024 [29][30]

Core Viewpoint - XOMA Royalty Corporation will report its fourth quarter and full year 2025 financial results on March 18, 2026, and will host a webcast to discuss these results and provide a business update [1]. Company Overview - XOMA Royalty Corporation is a biotechnology royalty aggregator that aids biotech companies in improving human health by acquiring potential future economics associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies [3]. - The company provides non-dilutive, non-recourse funding to sellers, which can be utilized to advance their internal drug candidates or for general corporate purposes [3]. - XOMA Royalty has a growing portfolio of assets, defined as the rights to receive potential future economics linked to the advancement of underlying therapeutic candidates [3].

Core Insights - XOMA Royalty Corporation will have its Chief Investment Officer, Brad Sitko, presenting at the Jones Healthcare and Technology Innovation Conference on April 9, 2025 [1] - The presentation will be accessible online, and a replay will be available for 90 days post-event [2] Company Overview - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, assisting biotech companies in enhancing human health [3] - The company acquires future economic rights associated with therapeutic candidates that are licensed to pharmaceutical or biotechnology firms, providing sellers with non-dilutive, non-recourse funding [3] - XOMA has a growing portfolio of assets, defined as the rights to receive potential future economics linked to the advancement of therapeutic candidates [3]